HMN-214 50mg | ≥99%
CSNpharm
HMN-214 is a potent PLK1 inhibitor an average IC50 of 0.12 μM, and a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.
More Information Supplier Page
HMN-214 is a potent PLK1 inhibitor an average IC50 of 0.12 μM, and a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.
More Information Supplier Page
HMN-214 is a potent PLK1 inhibitor an average IC50 of 0.12 μM, and a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.
More Information Supplier Page
HMN-214 is a potent PLK1 inhibitor an average IC50 of 0.12 μM, and a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.
More Information Supplier Page
HMN-214 is a potent PLK1 inhibitor an average IC50 of 0.12 μM, and a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.
More Information Supplier Page
Delafloxacin is a fluoroquinolone antibiotic used to treat serious skin infections.
More Information Supplier Page
Delafloxacin is a fluoroquinolone antibiotic used to treat serious skin infections.
More Information Supplier Page
Delafloxacin is a fluoroquinolone antibiotic used to treat serious skin infections.
More Information Supplier Page
Go6983 is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ and PKCδ with IC50 of 7 nM, 7 nM, 6 nM and 10 nM, respectively and less potent to PKCζ and inactive to PKCμ.
More Information Supplier Page
Go6983 is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ and PKCδ with IC50 of 7 nM, 7 nM, 6 nM and 10 nM, respectively and less potent to PKCζ and inactive to PKCμ.
More Information Supplier Page
SC514 is a potent, reversible, ATP-competitive and highly selective IKK-β(IKK-2) inhibitor with IC50 value ranging in 3-12 µM.
More Information Supplier Page